Tacrolimus - Jina Pharmaceuticals/Intas Pharmaceuticals

Drug Profile

Tacrolimus - Jina Pharmaceuticals/Intas Pharmaceuticals

Alternative Names: Nanosomal tacrolimus; Tacrolimus liposomal

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Transplant rejection
  • Phase II Rheumatoid arthritis
  • Clinical Phase Unknown Atopic dermatitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Transplant-rejection in Unknown (PO)
  • 30 Aug 2016 Intas Pharmaceuticals and Jina Pharmaceuticals plans a phase II trial for Lichen planus (CTRI2015-09-006211)
  • 16 Aug 2016 Intas Pharmaceutical plans a clinical bioequivalence trial for Atopic dermatitis in India (Topical) (CTRI2016-03-006735)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top